A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three European countries, 2019.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
02 2023
Historique:
pubmed: 10 2 2023
medline: 14 2 2023
entrez: 9 2 2023
Statut: ppublish

Résumé

BackgroundThe World Health Organization European Action Plan 2020 targets for the elimination of viral hepatitis are that > 75% of eligible individuals with chronic hepatitis B (HBV) or hepatitis C (HCV) are treated, of whom > 90% achieve viral suppression.AimTo report the results from a pilot sentinel surveillance to monitor chronic HBV and HCV treatment uptake and outcomes in 2019.MethodsWe undertook retrospective enhanced data collection on patients with a confirmed chronic HBV or HCV infection presenting at one of seven clinics in three countries (Croatia, Romania and Spain) for the first time between 1 January 2019 and 30 June 2019. Clinical records were reviewed from date of first attendance to 31 December 2019 and data on sociodemographics, clinical history, laboratory results, treatment and treatment outcomes were collected. Treatment eligibility, uptake and case outcome were assessed.ResultsOf 229 individuals with chronic HBV infection, treatment status was reported for 203 (89%). Of the 80 individuals reported as eligible for treatment, 51% (41/80) were treated of whom 89% (33/37) had achieved viral suppression. Of 240 individuals with chronic HCV infection, treatment status was reported for 231 (96%). Of 231 eligible individuals, 77% (179/231) were treated, the majority of whom had received direct acting antivirals (99%, 174/176) and had achieved sustained virological response (98%, 165/169).ConclusionTreatment targets for global elimination were missed for HBV but not for HCV. A wider European implementation of sentinel surveillance with a representative sample of sites could help monitor progress towards achieving hepatitis control targets.

Identifiants

pubmed: 36757314
doi: 10.2807/1560-7917.ES.2023.28.6.2200184
pmc: PMC9912376
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Antimicrob Chemother. 2019 Nov 1;74(Suppl 5):v17-v23
pubmed: 31782500
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1909-1911
pubmed: 30292889
Epidemiol Infect. 2017 Oct;145(14):2873-2885
pubmed: 28891457
Gastroenterol Clin North Am. 2015 Dec;44(4):807-24
pubmed: 26600221
Clin Infect Dis. 2021 Mar 1;72(5):755-763
pubmed: 32060534
Dig Liver Dis. 2015 Sep;47(9):741-3
pubmed: 26138800
BMC Infect Dis. 2017 Dec 20;17(1):784
pubmed: 29262788
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
BMC Health Serv Res. 2019 Oct 28;19(1):765
pubmed: 31660966
J Viral Hepat. 2018 May;25(5):482-490
pubmed: 29239130
Hepatology. 2016 Jan;63(1):284-306
pubmed: 26566246
BMC Med. 2017 May 3;15(1):92
pubmed: 28464883
MMWR Morb Mortal Wkly Rep. 2018 Jul 20;67(28):773-777
pubmed: 30025413
Lancet Infect Dis. 2016 Dec;16(12):1409-1422
pubmed: 27615026
Clin Gastroenterol Hepatol. 2013 May;11(5):565-71
pubmed: 23333662
Aust N Z J Public Health. 2020 Feb;44(1):59-64
pubmed: 31535439
Lancet. 2019 Apr 6;393(10179):1453-1464
pubmed: 30765123
Infect Dis (Lond). 2020 Sep;52(9):625-637
pubmed: 32644030
World J Hepatol. 2016 Jan 28;8(3):139-47
pubmed: 26839638
Hepatology. 2014 Apr;59(4):1343-50
pubmed: 24214920
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Euro Surveill. 2017 Jul 27;22(30):
pubmed: 28797326
J Hepatol. 2013 Mar;58(3):593-608
pubmed: 23419824
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875

Auteurs

Anthony Nardone (A)

Epiconcept, Paris, France.

Lina Nerlander (L)

European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Erika Duffell (E)

European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Marta Valenciano (M)

Epiconcept, Paris, France.

Maria Buti (M)

Hospital Universitario Valle Hebrón & CIBEREHD del Instituto Carlos III, Barcelona, Spain.

Cristina Marcos-Fosch (C)

Hospital Universitario Valle Hebrón & CIBEREHD del Instituto Carlos III, Barcelona, Spain.

Tatjana Nemeth-Blažić (T)

Croatian Institute of Public Health, Zagreb, Croatia.

Odette Popovici (O)

National Institute of Public Health, Bucharest, Romania.

Adriana Vince (A)

University Hospital for Infectious Diseases, Medical School University of Zagreb, Croatia.

Petruta Violeta Filip (PV)

University Emergency Hospital, Bucharest, Romania.

Tajana Filipec (T)

Clinical Hospital Merkur, School of Medicine, University of Zagreb, Zagreb, Croatia.

Mirjana Lana Kosanović Ličina (ML)

Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia.

Boris Luksic (B)

Clinical Hospital Centre Split, School of Medicine University of Split, Split, Croatia.

Diana Nonković (D)

Teaching Institute of Public Health Split and Dalmatia county, University Department of Health Studies, Split, Croatia.

Corina Silvia Pop (CS)

University Emergency Hospital, Bucharest, Romania.

Fabiana Radu (F)

University Emergency Hospital, Bucharest, Romania.

Irina Teodorescu (I)

Clinical Infectious Diseases Hospital, Iasi, Romania.

Adriana Violeta Topan (AV)

"Iuliu Hatieganu" University of Medicine and Pharmacy, Hospital of Infectious Diseases, Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH